• Pre Clinical And Clinical Research

Enterprise Therapeutics appoints Dr David Morris MD as Chief Medical Officer

Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of patients suffering with respiratory disease, today announced it has appointed Dr David Morris MD as Chief Medical Officer to lead the Company’s respiratory programmes.

Impact of the ATTC Network after 18 months of operation

Just 18 months ago, the Advanced Therapy Treatment Centre (ATTC) network was set up through funding from the UK Research and Innovation Industrial Strategy Challenge Fund.

Enterprise Therapeutics publishes paper on novel therapeutic approach for treatment of all cystic fibrosis patients

Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of patients suffering with respiratory disease, today announced the publication of its first peer-reviewed paper. The open access paper, published in the American Journal of Respiratory and Critical Care Medicine1, describes TMEM16A potentiation via ETX001 as a novel approach for the treatment of cystic fibrosis (CF).

CGT Catapult hosts second annual workshop to address digital challenges in adoption of advanced therapies by the NHS

Experts addressed different possible models for optimising data collection to support the adoption of cell and gene therapies in the UK. Barriers to digital integration, post-launch data collection and outcomes-based reimbursement were the primary focus of the day.

Repositive partners with Scientist.com to offer pharma and biotech researchers access to industry-leading directory of preclinical cancer models

Repositive announced today that its directory of over 5,300 preclinical cancer models is now available on Scientist.com, the world’s largest marketplace for outsourced R&D. By leveraging Scientist.com’s community of researchers, as well as its innovative tools for streamlining the outsourcing process, this partnership will further support Repositive's mission to connect pharma and biotechs worldwide with the right cancer models for their drug development programmes.

Prokarium announces MHRA acceptance to run Phase I trial of lead vaccine against enteric fever

Prokarium, a private biotechnology company developing vaccines against infectious diseases and immunotherapy for solid tumors, has received Clinical Trial Authorization (CTA) acceptance from the UK Medicines and Healthcare products Regulatory Agency (MHRA) to run a first-in-human Phase I trial with Entervax™, a bivalent vaccine against enteric fever.

AMR Centre candidate targets superbugs with problem metallo-β-lactamase enzymes

The AMR Centre has nominated a preclinical candidate in its program that tackles drug resistance conferred by NDM-1 and other metallo-β-lactamases (MBL).

£1.2m investment to reinforce Stevenage Campus as world class cell and gene therapy hub

Hertfordshire Local Enterprise Partnership is to invest £1.2m into Stevenage Bioscience Catalyst (SBC) to help grow a world-class cell and gene therapy cluster. The £1.2m Local Growth Fund investment will provide much-needed temporary accommodation for growing cell and gene therapy companies, strengthening the UK’s sectorial advantage and Hertfordshire’s position within the Oxford-London-Cambridge golden research triangle.

Repositive unveils molecular search functionality for its Cancer Models Platform at ELRIG Drug Discovery

Repositive is unveiling molecular search functionality for its Cancer Models Platform today at ELRIG Drug Discovery. The first version of this innovative feature enables pharma and biotech scientists to search Repositive’s cancer model directory by their gene of interest and explore different mutations available to ensure they source a cancer model with the right molecular profile for their preclinical study.

Dr Stefan Symeonides to guide MedAnnex’s Phase I trial preparation

Edinburgh-based biotechnology company MedAnnex Ltd today announced that Dr Stefan Symeonides, a Senior Clinical Lecturer at the University of Edinburgh, will provide expert advice as the company prepares for Phase I clinical trials. Dr Symeonides is a Phase I trial specialist with a focus on immunotherapy and leads the Edinburgh Cancer Centre Phase I trials unit.